You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格醫藥(03347.HK)2024年度純利跌79.99%至4.05億元
格隆匯 03-27 18:31

格隆匯3月27日丨泰格醫藥(03347.HK)公佈年度業績,截至2024年12月31日止年度,公司收入為人民幣66.03億元,同比減少10.6%;毛利為22.42億元,同比減少21.3%;公司擁有人應占利潤為人民幣4.05億元,同比減少79.99%;每股盈利為人民幣0.47元。

從地域來看,公司於中國的收入由同期的人民幣42.345億元減至報吿期間的人民幣35.479億元,同比下降16.2%。於中國的收入減少主要是由於報吿期間公司於中國的臨牀試驗技術服務分部收入同比下降。

報吿期間,境外收入由同期的人民幣31.495億元減至人民幣30.552億元,同比下降3.0%。公司於同期產生部分與特定疫苗項目相關的收入,以及剔除該等項目後,公司境外業務收入於報吿期間實現同比增長。

截至2024年12月31日,公司有536個藥物臨牀研究項目在境內開展,295個項目在境外開展,其中有233個項目在境外(主要於南韓、澳大利亞、東南亞、歐洲及美國)進行單一區域臨牀試驗,以及有62項目在亞太地區、北美洲、歐洲及非洲進行多區域臨牀試驗,涉及治療領域包括腫瘤、呼吸、心血管、內分泌、風濕免疫、感染、罕見疾病及疫苗等。截至2024年12月31日,正在進行的海外藥物臨牀研究項目數量較截至2023年12月31日的數量顯着增加,説明公司在全球化戰略方面取得進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account